



CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, April 20, 2026

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

### **OTHER RELEVANT INFORMATION**

Pharma Mar, S.A. announces that the Australian Therapeutic Goods Administration (TGA) and the Health Sciences Authority (HSA) in Singapore have granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

**Pharma Mar S.A.**  
**Avda. de los Reyes, 1**  
**P.I. La Mina**  
**28770 Colmenar Viejo**  
**(Madrid) Spain**  
**[www.pharmamar.com](http://www.pharmamar.com)**

# PharmaMar's Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) has obtained another three approvals as first-line maintenance therapy for small cell lung cancer

- **Australia, Singapore and the Dominican Republic are the latest countries to adopt the approvals for commercialization.**
- **The treatment is now available in 13 countries.**

**Madrid, April 20<sup>th</sup>, 2026.-** PharmaMar (MSE:PHM) has announced that the Australian Therapeutic Goods Administration (TGA) and the Health Sciences Authority (HSA) in Singapore have granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

The approvals are based on the results from the Phase 3 IMforte<sup>i</sup> trial.

PharmaMar's partner in Australia and Singapore, Specialised Therapeutics Asia Pte, Ltd (STA), will market and commercialize the product.

These approvals were obtained under the Orbis Project, an initiative of the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence, designed to provide a framework for concurrent submission and review of oncology products among international partners. As of today, this treatment is approved in a total of 13 countries: the US, Switzerland, the United Arab Emirates, Oman, Uruguay, Peru, Paraguay, Ecuador, Israel, Taiwan, Australia, Singapore and Dominican Republic.

PharmaMar also received a recommendation for approval from the European Medicines Agency in March. The European Commission will now decide on the marketing authorization in accordance with the established procedure.

**Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

**About PharmaMar**

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com)

**About Zepzelca®**

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.


Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

**Media Contact:**

Lara Vadillo – Communications director [lvadillo@pharmamar.com](mailto:lvadillo@pharmamar.com)  
Phone: +34 918466000

**Capital Markets & Investor Relations:**

José Luis Moreno – VP Capital Markets & Investor Relations  
Natalia Amo – Capital Markets & Investor Relations  
[investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)  
Phone: +34 914444500





Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)

---

[i Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer \(IMforte\): a randomised, multicentre, open-label, phase 3 trial - The Lancet](#)